|
|
Vaccine Detail
|
MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine |
| Vaccine Information |
- Vaccine Name: MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007548
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- MAGEA3
gene engineering:
- Type: Recombinant protein preparation
- Description: (Wei et al., 2019)
- Detailed Gene Information: Click Here.
- CTAG1B
gene engineering:
- Type: Recombinant protein preparation
- Description: (Wei et al., 2019)
- Detailed Gene Information: Click Here.
- MAGEA1 (MAGE1)
gene engineering:
- Type: Recombinant protein preparation
- Description: (Wei et al., 2019)
- Detailed Gene Information: Click Here.
- Description: A cancer vaccine comprised of synthetic peptides derived from human melanoma antigen A1 (MAGE-A1), human melanoma antigen A3 (MAGE-A3) and cancer-testis antigen NY-ESO-1 with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A1/MAGE-A3/NY-ESO-1 peptides vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A1, MAGE-A3 and NY-ESO-1, resulting in tumor cell lysis. The MAGE-A1, MAGE-A3, and NY-ESO-1 tumor-associated antigens (TAAS) are overexpressed by a variety of cancer cell types. (NCIT_C84854).
|
| Host Response |
|
|
| References |
NCIT_C84854: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C84854]
Wei et al., 2019: Wei X, Chen F, Xin K, Wang Q, Yu L, Liu B, Liu Q. Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects. Translational oncology. 2019; 12(5); 733-738. [PubMed: 30877975].
|
|
